NZ733825A - Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors - Google Patents
Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitorsInfo
- Publication number
- NZ733825A NZ733825A NZ733825A NZ73382515A NZ733825A NZ 733825 A NZ733825 A NZ 733825A NZ 733825 A NZ733825 A NZ 733825A NZ 73382515 A NZ73382515 A NZ 73382515A NZ 733825 A NZ733825 A NZ 733825A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pharmaceutical formulations
- trk
- related kinase
- inhibitors
- tropomyosin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 102000005937 Tropomyosin Human genes 0.000 title abstract 2
- 108010030743 Tropomyosin Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- HVRWZFQFSQUILC-UHFFFAOYSA-N 3-[[3-methoxy-4-[(4-methoxyphenyl)methoxy]phenyl]methyl]-6-(1-methylpyrazol-4-yl)imidazo[4,5-b]pyridin-2-amine Chemical compound COC=1C=C(CN2C(=NC=3C2=NC=C(C3)C=3C=NN(C3)C)N)C=CC1OCC1=CC=C(C=C1)OC HVRWZFQFSQUILC-UHFFFAOYSA-N 0.000 abstract 2
- 238000013265 extended release Methods 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000004005 microsphere Substances 0.000 abstract 1
- 150000004682 monohydrates Chemical group 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462093801P | 2014-12-18 | 2014-12-18 | |
| PCT/US2015/066396 WO2016100677A2 (en) | 2014-12-18 | 2015-12-17 | Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ733825A true NZ733825A (en) | 2022-02-25 |
Family
ID=55080206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ733825A NZ733825A (en) | 2014-12-18 | 2015-12-17 | Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US10219998B2 (enExample) |
| EP (1) | EP3233057A2 (enExample) |
| JP (1) | JP6606183B2 (enExample) |
| KR (1) | KR102561692B1 (enExample) |
| CN (2) | CN107231803B (enExample) |
| AR (1) | AR103176A1 (enExample) |
| AU (1) | AU2015364557C1 (enExample) |
| BR (1) | BR112017012566B1 (enExample) |
| CA (1) | CA2970938C (enExample) |
| CL (1) | CL2017001543A1 (enExample) |
| CO (1) | CO2017007118A2 (enExample) |
| EA (1) | EA201791336A1 (enExample) |
| IL (1) | IL252901B (enExample) |
| MA (1) | MA40698A3 (enExample) |
| MX (2) | MX387694B (enExample) |
| MY (1) | MY195799A (enExample) |
| NZ (1) | NZ733825A (enExample) |
| PH (1) | PH12017501121B1 (enExample) |
| SG (1) | SG11201704872RA (enExample) |
| TN (1) | TN2017000234A1 (enExample) |
| TW (2) | TWI696621B (enExample) |
| WO (1) | WO2016100677A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI663159B (zh) | 2013-12-10 | 2019-06-21 | 美商健臻公司 | 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑 |
| TWI696621B (zh) | 2014-12-18 | 2020-06-21 | 美商健臻公司 | 原肌球蛋白相關激酶（ｔｒｋ）抑制劑之醫藥調配物 |
| CN110156813B (zh) * | 2018-02-13 | 2023-07-25 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| AR114110A1 (es) | 2018-02-28 | 2020-07-22 | Lilly Co Eli | Anticuerpo anti-trka |
| EP4180428A1 (en) | 2021-11-12 | 2023-05-17 | Genzyme Corporation | Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions |
| CN114712365B (zh) * | 2022-06-07 | 2022-08-23 | 山东绿叶制药有限公司 | Trk抑制剂在制备治疗迟发性运动障碍药物中的应用 |
| US20240383892A1 (en) * | 2023-05-17 | 2024-11-21 | Centrexion Therapeutics Corporation | PARTICLES OF IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4612323A (en) | 1983-06-27 | 1986-09-16 | Sumitomo Chemical Company, Limited | Insecticidal and acaricidal derivatives of 1-benzylbenzimidazole |
| JPS60158180A (ja) | 1984-01-30 | 1985-08-19 | Sumitomo Chem Co Ltd | ベンズイミダゾ−ル誘導体、その製造法およびそれを有効成分とする殺虫、殺ダニ剤 |
| JPS6117569A (ja) | 1984-07-03 | 1986-01-25 | Sumitomo Chem Co Ltd | ベンズイミダゾ−ル誘導体およびそれを有効成分とする殺ダニ剤 |
| JPS6117569U (ja) | 1984-07-05 | 1986-02-01 | エヌオーケー株式会社 | バルブ装置 |
| JPS61151176A (ja) | 1984-12-24 | 1986-07-09 | Sumitomo Chem Co Ltd | ベンズイミダゾール誘導体およびそれを有効成分とする殺虫、殺ダニ剤 |
| DE4219534A1 (de) | 1992-02-19 | 1993-12-16 | Thomae Gmbh Dr K | Substituierte Biphenylylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DK154092D0 (da) | 1992-12-23 | 1992-12-23 | Neurosearch As | Imidazolforbindelser, deres fremstilling og anvendelse |
| US5702637A (en) | 1995-04-19 | 1997-12-30 | Minnesota Mining And Manufacturing Company | Liquid crystal compounds having a chiral fluorinated terminal portion |
| IL133575A0 (en) | 1997-06-27 | 2001-04-30 | Fujisawa Pharmaceutical Co | Sulfonamide compounds, a method for producing same and pharmaceutical compositions containing same |
| TW589309B (en) | 1997-07-03 | 2004-06-01 | Bristol Myers Squibb Pharma Co | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| US7030150B2 (en) | 2001-05-11 | 2006-04-18 | Trimeris, Inc. | Benzimidazole compounds and antiviral uses thereof |
| RU2315746C2 (ru) | 2001-08-09 | 2008-01-27 | Оно Фармасьютикал Ко., Лтд. | Производные карбоновых кислот и фармацевтическое средство, содержащее их в качестве активного ингредиента |
| GB0122190D0 (en) | 2001-09-14 | 2001-10-31 | Qinetiq Ltd | Novel compounds |
| US20040002145A1 (en) | 2002-03-18 | 2004-01-01 | Shewchuk Lisa Marie | Crystal structure of liganded cFMS kinase domain |
| WO2003099276A1 (en) | 2002-05-10 | 2003-12-04 | Bristol-Myers Squibb Company | 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors |
| FR2852957B1 (fr) | 2003-03-31 | 2005-06-10 | Sod Conseils Rech Applic | Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament |
| TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
| WO2005095429A1 (ja) | 2004-03-31 | 2005-10-13 | Kissei Pharmaceutical Co., Ltd. | フェノール誘導体、それを含有する医薬組成物及びその医薬用途 |
| NZ550769A (en) | 2004-05-07 | 2010-06-25 | Warner Lambert Co | 3- or 4-Monosubstituted phenol and thiophenol derivatives useful as H3 ligands |
| AU2005307818A1 (en) | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Heterocyclylbiphenyl derivates as protein Tyrosine phosphatase inhibitors |
| ES2308731T3 (es) | 2005-02-16 | 2008-12-01 | Astrazeneca Ab | Compuestos quimicos. |
| JP2006273879A (ja) | 2005-03-25 | 2006-10-12 | Fuji Photo Film Co Ltd | カラー表示素子及びカラー表示方法 |
| CA2623958C (en) | 2005-09-30 | 2013-05-28 | Banyu Pharmaceutical Co., Ltd. | 2-heteroaryl-substituted indole derivative |
| CN1947717B (zh) | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
| WO2008121333A1 (en) | 2007-03-30 | 2008-10-09 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
| JP2010524911A (ja) * | 2007-04-18 | 2010-07-22 | アストラゼネカ アクチボラグ | ５−アミノピラゾール−３−イル−３Ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体と癌の治療のためのその使用 |
| WO2009026720A1 (en) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| UA109775C2 (xx) | 2009-10-29 | 2015-10-12 | N-вмісні гетероарильні похідні як інгібітори jak3-кінази | |
| RU2012120784A (ru) | 2009-11-12 | 2013-12-20 | Селвита С.А. | Соединение, способ его получения, фармацевтическая композиция, применение соединения, способ модулирования или регулирования сериновых/треониновых киназ и средство, модулирующее сериновые/треониновые киназы |
| US8604217B2 (en) | 2009-11-12 | 2013-12-10 | Selvita S.A. | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| CA2803448A1 (en) | 2010-07-06 | 2012-01-12 | Universite De Montreal | Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators |
| KR20130133905A (ko) | 2011-04-05 | 2013-12-09 | 화이자 리미티드 | 트로포미오신-관련 키나제의 억제제인 피롤로[2,3-d]피리미딘 유도체 |
| CA2858958C (en) | 2011-12-12 | 2016-10-04 | Dr. Reddy's Laboratories Ltd. | Substituted pyrazolo[1,5-a]pyridine as tropomyosin receptor kinase (trk) inhibitors |
| WO2013176970A1 (en) * | 2012-05-22 | 2013-11-28 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| JP6117569B2 (ja) | 2013-02-28 | 2017-04-19 | 三甲株式会社 | ボックスパレット |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| TWI663159B (zh) | 2013-12-10 | 2019-06-21 | 美商健臻公司 | 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑 |
| TWI696621B (zh) | 2014-12-18 | 2020-06-21 | 美商健臻公司 | 原肌球蛋白相關激酶（ｔｒｋ）抑制劑之醫藥調配物 |
| CN107197528B (zh) | 2016-03-14 | 2020-12-25 | 华为技术有限公司 | 一种资源调度和分配的方法和装置 |
-
2015
- 2015-12-17 TW TW104142525A patent/TWI696621B/zh active
- 2015-12-17 NZ NZ733825A patent/NZ733825A/en unknown
- 2015-12-17 CN CN201580076248.9A patent/CN107231803B/zh active Active
- 2015-12-17 MX MX2017008058A patent/MX387694B/es unknown
- 2015-12-17 CA CA2970938A patent/CA2970938C/en active Active
- 2015-12-17 TW TW109118415A patent/TWI780438B/zh active
- 2015-12-17 SG SG11201704872RA patent/SG11201704872RA/en unknown
- 2015-12-17 MY MYPI2017702037A patent/MY195799A/en unknown
- 2015-12-17 TN TN2017000234A patent/TN2017000234A1/en unknown
- 2015-12-17 JP JP2017532722A patent/JP6606183B2/ja active Active
- 2015-12-17 KR KR1020177019802A patent/KR102561692B1/ko active Active
- 2015-12-17 EP EP15823088.8A patent/EP3233057A2/en active Pending
- 2015-12-17 CN CN201911088940.XA patent/CN110950862B/zh active Active
- 2015-12-17 US US15/536,544 patent/US10219998B2/en active Active
- 2015-12-17 AU AU2015364557A patent/AU2015364557C1/en active Active
- 2015-12-17 EA EA201791336A patent/EA201791336A1/ru unknown
- 2015-12-17 MA MA40698A patent/MA40698A3/fr unknown
- 2015-12-17 BR BR112017012566-8A patent/BR112017012566B1/pt active IP Right Grant
- 2015-12-17 WO PCT/US2015/066396 patent/WO2016100677A2/en not_active Ceased
- 2015-12-18 AR ARP150104196A patent/AR103176A1/es not_active Application Discontinuation
-
2017
- 2017-06-14 IL IL252901A patent/IL252901B/en active IP Right Grant
- 2017-06-14 CL CL2017001543A patent/CL2017001543A1/es unknown
- 2017-06-15 PH PH12017501121A patent/PH12017501121B1/en unknown
- 2017-06-16 MX MX2020013015A patent/MX2020013015A/es unknown
- 2017-07-17 CO CONC2017/0007118A patent/CO2017007118A2/es unknown
-
2019
- 2019-01-04 US US16/239,904 patent/US11110055B2/en active Active
-
2021
- 2021-08-20 US US17/407,419 patent/US11793749B2/en active Active
-
2023
- 2023-10-20 US US18/491,503 patent/US20240189223A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501121A1 (en) | Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors | |
| ZA201800022B (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| WO2016142855A3 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
| PH12017550028A1 (en) | Solid forms of an ask1 inhibitor | |
| ZA201700035B (en) | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof | |
| SI3305785T1 (sl) | Derivat pirido(3,4-D)pirimidina in njegova farmacevtsko sprejemljiva sol | |
| PH12016502523A1 (en) | Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide | |
| PH12017501816B1 (en) | Azabenzimidazoles and their use as ampa receptor modulators | |
| SI3357922T1 (sl) | 2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino) pirido(2,3-D)pirimidin-7(8H)-on derivati in sorodne spojine kot CDK4 inhibitorji za zdravljenje tumorjev | |
| MX2016009581A (es) | Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso. | |
| MX2015012896A (es) | Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa. | |
| IL280513A (en) | Imidazo[2,1-B]pyridazines as TRK inhibitors | |
| MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
| WO2014093870A3 (en) | Use of c-c chemokine receptor type 7 (ccr7) inhibitors | |
| HK1236034A1 (en) | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | |
| HK1236035A1 (en) | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2023 BY COMPUTER PACKAGES INC Effective date: 20221130 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2024 BY COMPUTER PACKAGES INC Effective date: 20231130 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2025 BY COMPUTER PACKAGES INC Effective date: 20241130 |